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Taoyuan and 5) Department of Laboratory Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TaiwanAbstractThe characteristics of patients with recurrent bacteraemia caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli or
Klebsiella pneumoniae (EK) are rarely described. Flomoxef belongs to the cephamycins group and demonstrates in vitro activity against
ESBL-producing organisms. Whether ﬂomoxef may be used for the treatment of such infections remains controversial. This retrospective
case–control study enrolled adult patients who had bacteraemia caused by ESBL-EK during 2005–2011. Case patients were those who
had more than one episode of ESBL-EK bacteraemia. Controls were those who were matched for age and interval time of blood
sampling and had only one episode of ESBL-EK bacteraemia with subsequent bacteraemia episodes caused by other non-ESBL-EK
bacteria. Pulsed-ﬁeld gel electrophoresis and microbiologic proﬁles of the initial and subsequent ESBL-EK isolates were analysed. During
the study period, 424 patients were found to have at least one positive blood culture after the ﬁrst ESBL-EK bacteraemia episode, and 67
(15.8%) had a second episode of ESBL-EK bacteraemia. Bacteraemia resulting from vascular catheter–related infection (odds ratio, 3.24;
95% conﬁdence interval, 1.31–8.05), and deﬁnitive therapy with ﬂomoxef (odds ratio, 2.99; 95% conﬁdence interval, 1.10–8.15) were
both independent risk factors for the recurrence. Among the 56 patients with available ESBL-EK isolates for analysis, 38 (67.8%) were
infected by genetically similar strains. In three of these 38 recurrent ESBL-EK bacteraemia cases caused by an identical strain, the
minimum inhibitory concentrations of carbapenem for the subsequent K. pneumoniae isolates were fourfold or higher than the initial
isolates. Recurrent bacteraemia was not uncommon in our patients with ESBL-EK bacteraemia, and most of the episodes were caused by
identical strains.
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extended-spectrum β-lactamase (ESBL)-producing Enter-
obacteriaceae, mainly Escherichia coli (EC) and Klebsiella pneumo-
niae (KP), have been increasing in the last decade [1]. Clinical
isolates of ESBL-producing Enterobacteriaceae are often
concomitantly resistant to many classes of antibiotics, such as
ﬂuoroquinolones and aminoglycosides, adding to the difﬁcultiesClin Microbiol Infect 2015; 21: 1105.e1–1105.e8
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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or deﬁnitive therapy [2]. Carbapenems are the recommended
agents for treatment in such situations [1]. Cephamycins (e.g.
cefoxitin, cefmetazole, ceftotetan and ﬂomoxef) are a group of
β-lactam antibiotics that have been shown to be stable against
ESBL-producing organisms [3,4]. Flomoxef with oxygen
substituted for the sulphur, a 7-a˛-methoxy group in the cepha-
losporin core and a diﬂuroromethylthio-acetamido group at
position 7 provides better in vitro activity against ESBL-producing
Enterobacteriaceae [3]. However, whether it is appropriate to
use cephamycins or other agents instead of carbapenems for the
treatment of such infections remains controversial.
ESBL-producing organisms can be disseminated by clonal
spread, plasmid transmission or gene transfer via transposons
[5]. Evidence shows that patients may develop recurrent bac-
teraemia by ESBL-KP, and reduced susceptibility to ertapenem
can occur in ESBL-KP isolates identiﬁed in the second episode
of bacteraemia [6]. A previous study has reported a substantial
rate (12%) of recurrent bacteraemia, and several independent
predictors have been identiﬁed, including healthcare-associated
origins, polymicrobial Gram-positive or fungal aetiology, inap-
propriate empirical antimicrobial therapy, related infection foci
within the abdomen or endocardium and the use of intravenous
catheters [7]. Other studies have demonstrated that recurrent
bacteraemia occurs at a rate of 2.3% to 20.3% for a variety of
speciﬁc pathogens [8–12]. However, the incidence and risk
factors associated with recurrent bacteraemia by ESBL-EC or
ESBL-KP have not yet been clariﬁed.
The aims of this hospital-based study were to identify the
risk factors associated with recurrent bacteraemia by ESBL-EC
or ESBL-KP organisms among a cohort of ESBL-EC or ESBL-KP
bacteraemic patients and to assess the impact of antibiotic use
on the occurrence of such recurrent bacteraemia. Microbio-
logic proﬁles of the bacterial isolates with recurrent bacter-
aemia caused by identical strains were also analysed.Materials and MethodsStudy design and patients
The study was conducted at Kaohsiung Chang Gung Memorial
Hospital, a 2700-bed tertiary-care medical center in southern
Taiwan. The institutional review board of the Chang Gung
Memorial Hospital approved the study (no. 99-4102B).
During 2005–2011, 614 adult patients aged 18 years or more
with one or more episodes of bacteraemia caused by ESBL-EC
or ESBL-KP were identiﬁed. Among them, 424 patients
(69.1%) had at least one blood culture repeated after the ﬁrst
episode of bacteraemia due to ESBL-EC or ESBL-KP; of these, 67
(15.8%) had a second episode of ESBL-EC or ESBL-KPClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectbacteraemia. The 34 patients with recurrent ESBL-EC bacter-
aemia and 33 with recurrent ESBL-KP bacteraemia were
included as case patients. The duration from the cessation of
antimicrobial therapy to the subsequent episode of bacteraemia
was 56 ± 27 days. For each case patient, one control patient
matched for age, aetiologic agent of the ﬁrst bacteraemia episode
and the time intervals between blood samplings was chosen
among those who had only one episode of ESBL-EC or ESBL-KP-
positive blood culture but had subsequent bacteraemia episodes
due to other non-ESBL-producing bacteria. For case patients
with multiple episodes of ESBL-EC or ESBL-KP bacteraemia,
clinical features of the ﬁrst episode were used for analysis.
Selection of antimicrobial regimens was at the discretion of
the attending physician, and all prescription of antimicrobial
agents had to be approved by infectious disease specialists for
their indication, dosages and administration through the estab-
lished antimicrobial stewardship system in this hospital [13].
Deﬁnitions
A breakthrough bacteraemia was deﬁned as blood cultures
yielding the same pathogens within 14 days of the ﬁrst bac-
teraemia onset in a patient who, for at least the previous 48
hours, had been receiving an antibiotic to which the isolated
microorganism was susceptible. Deﬁnitive therapy was deﬁned
as antibiotic therapy with in vitro activity administered after the
receipt of ﬁnal blood culture results. Sources of bacteraemia
were identiﬁed according to clinical, microbiologic and/or im-
aging ﬁndings. The growth of an ESBL-EC or ESBL-KP from a
patient in whom no apparent infection focus other than blood
was identiﬁed was deﬁned as a bacteraemia with no identiﬁed
focus of infection; otherwise, it was referred to as a bacter-
aemia with identiﬁed focus of infection. Pneumonia referred to
the presence of clinical symptoms or signs of lower respiratory
tract infection, accompanied by consistent radiographic mani-
festations. Intravenous catheterization was considered as the
source of bacteraemia if the inserted catheter had been in place
for 72 hours, and the culture by rolling the clipped 5 cm
distant tip of the removed catheter on a culture medium yiel-
ded 15 colonies of ESBL-producing organisms; or the culture
of purulent discharge from the catheter exit grew ESBL-
producing Enterobacteriaceae [14]. The diagnosis of urinary
tract infection was based on the detection of the ESBL-
producing bacteria that grew in the quantity of 105 colony-
forming units (CFU) per millilitre in the urine culture in the
presence of clinical symptoms. Catheter-related urinary tract
infection was urinary tract infection diagnosed in patients with
indwelling urethral catheterization who presented with symp-
toms or signs consistent with urinary tract infection but
without other identiﬁed source of infection, along with 103
CFU/mL of ESBL-EC or ESBL-KP in a single catheterized urineious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1105.e1–1105.e8
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infection, was considered to be caused by ESBL-producing
isolates when the bacteria grew from the specimen sampled
from the affected site. Intra-abdominal infections represented a
wide variety of pathologic conditions that involved lesions of all
the intra-abdominal organs, which included inﬂammation of
single organs and/or any sort of peritonitis, as well as include
intraperitoneal, retroperitoneal and parenchymal abscesses.
Identiﬁcation of bacteria and pulsed-ﬁeld gel
electrophoresis
All EC and KP isolates were identiﬁed by biochemical tests and
conﬁrmed using the Vitek system (bioMérieux, Marcy l’Etoile,
France). The PulseNet pulsed-ﬁeld gel electrophoresis (PFGE)
protocol for Enterobacteriaceae was followed [16]. NotI and
XbaI were used as the restriction enzymes for EC and KP,
respectively. The PFGE pattern was considered unique if it had
four or more bands that differed from the others. The patho-
gens of recurrent bacteraemia were classiﬁed on the basis of
the PFGE pattern as either different strains (if the pattern of the
subsequent isolate differed from that of the initial isolate) or
identical strains (if the patterns of the initial and subsequent
isolates were indistinguishable or varied by three or fewer
bands).
Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MICs) of imipenem, mer-
openem, ertapenem, piperacillin–tazobactam and ciproﬂoxacin
were determined using Etest strips (AB Biodisk, Solna, Sweden)
[17]. MICs of ﬂomoxef were determined using a standard broth
microdilution method and interpreted as described previously
(susceptible, MIC 8 mg/L) [18]. ESBL production was evaluated
using the screening and conﬁrmation tests suggested by the
Clinical and Laboratory Standards Institute [19]. The modiﬁed
Hodge test was used to detect carbapenemase production [17].
Isolates were screened for AmpC and metallo-β-lactamases
(MBLs) using the boronic acid disk method and the 2-
mercaptopropionic acid double disk method, respectively [20,21].
PCR-speciﬁc β-lactamase genes
Primers were used for PCR detection of three ESBL genes
(blaSHV, blaTEM and blaCTX-M) [22]. Multiplex PCR was used to
detect the presence of plasmid-mediated AmpC β-lactamase
genes [23] and MBL genes (blaIMP, blaVIM and blaKPC) [24]. We
also screened for class D β-lactamase (OXA-48) [25].
Detection of plasmid-mediated quinolone-resistance
determinants
PCR ampliﬁcation was used in all available isolates to detect the
qnrA, qnrB, qnrS, qepA, aac(60)-Ib, armA and rmtB genes [26].Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfeAnalysis of PCR-restriction fragment length polymorphisms was
used to determine the presence of qnrB variants and aac(60)-Ib-
cr alleles [26].
Analysis of outer membrane protein (OMP) proﬁles
Two pairs of previously described primers were used for PCR
ampliﬁcation and sequence analysis to examine the DNA se-
quences of OmpC/OmpF and OmpK35/OmpK36 genes of
ertapenem-resistant EC and KP, respectively [27].
Statistical analysis
Continuous variables were expressed as the mean ± standard
deviation and compared by Student’s t test. Categorical vari-
ables were expressed as numbers and percentages and
compared by the chi-square test or Fisher’s exact test. All
variables with a p value of 0.10 or less in univariate analyses
were entered into a multivariate logistic regression model. p
<0.05 was considered signiﬁcant. Goodness of ﬁt was assessed
by the Hosmer and Lemeshow statistic. A receiver operating
characteristic curve analysis was used to evaluate the predictive
performance of the logistic regression model.ResultsComparison of patients with recurrent and
nonrecurrent ESBL-EC or ESBL-KP bacteraemia
Demographic and clinical features of the case and control pa-
tients are listed in Table 1. The majority of the clinical char-
acteristics were similar between the two groups. In the
multivariate analysis, bacteraemia resulting from vascular cath-
eter–related infection (odds ratio (OR), 3.24; 95% conﬁdence
interval (CI), 1.31–8.05; p 0.01), and deﬁnitive therapy with
ﬂomoxef (OR, 2.99; 95% CI, 1.10–8.15; p 0.03) were both
associated with recurrent bacteraemia due to ESBL-KP or
ESBL-EC. Onset of bacteraemia in the intensive care unit and
antimicrobial therapy with glycopeptides or extended-spectrum
cephalosporins within 4 weeks before the bacteraemia, though
more frequently seen in the case patients than the control
patients, were not signiﬁcantly associated with recurrent bac-
teraemia due to ESBL-KP or ESBL-EC in the multivariate
analysis.
Comparison of patients with recurrent ESBL-EC or
ESBL-KP bacteraemia: identical strains versus different
strains
A total of 74 EC and 42 KP isolates identiﬁed from 56 of the 67
patients with recurrent ESBL-EC or ESBL-KP bacteraemia
were available for laboratory analysis. PFGE analysis revealed
diverse genotypes among the ESBL-EC and ESBL-KP isolatesctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1105.e1–1105.e8
TABLE 1. Demographic and clinical characteristics of 134 adult patients with recurrent (cases) or nonrecurrent (controls)
bacteraemia caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae
Characteristic
Cases
(n [ 67)
Controls
(n [ 67)
Univariate analysis Multivariate analysis
p
OR
(95% CI) p
OR
(95% CI)
Age (years) 62.1 ± 17.8 62.2 ± 15.4 0.93
Male 40 (59.7) 43 (64.2) 0.72
Hospital-acquired infection 55 (82.1) 61 (91.0) 0.20
Antimicrobial resistance
Flomoxef 24 (35.8) 32 (47.8) 0.22
Ciproﬂoxacin 50 (74.6) 50 (74.6) >0.99
Piperacillin–tazobactam 9 (13.4) 11 (16.4) 0.81
Ertapenem 4 (5.9) 2 (2.9) 0.68
Polymicrobial bloodstream infection 13 (19.4) 13 (19.4) >0.99
Bacteraemia onset in ICU 49 (73.1) 37 (55.2) 0.05 2.21 (1.07–4.55) 0.09 2.11 (0.90–4.95)
Pittsburgh bacteraemic score 4 points 49 (73.1) 50 (74.6) >0.99
Comorbidity
Diabetes mellitus 32 (47.8) 26 (38.8) 0.38
Malignancy 26 (38.8) 26 (38.8) >0.99
Liver cirrhosis 13 (19.4) 9 (13.4) 0.49
Renal failure 25 (37.3) 21 (31.3) 0.59
Hemodialysis dependence 9 (13.4) 7 (10.4) 0.79
Potential bacteraemia sourcea
Vascular catheter–related infection 30 (44.8) 10 (14.9) <0.01 4.63 (2.02–10.53) 0.01 3.24 (1.31–8.05)
Removal of catheter within 72 hours
after bacteraemia for vascular catheter infection
18 (60.0) 4 (40.0) 0.30
No identiﬁed focus 20 (29.9) 18 (26.9) 0.85
Pneumonia 12 (17.9) 21 (31.3) 0.11
Urinary tract infection 21 (31.3) 24 (35.8) 0.72
Catheter-related urinary tract infection 12 (17.9) 16 (23.9) 0.52
Intra-abdominal infection 6 (8.9) 10 (14.9) 0.43
Skin and soft tissue infection 5 (.5) 7 (10.4) 0.76
Antimicrobial therapy within 4 weeks before bacteraemia
Glycopeptides 24 (35.8) 11 (16.4) 0.02 2.84 (1.25–6.45) 0.05 2.52 (0.99–6.45)
Carbapenems 16 (23.9) 16 (23.9) >0.99
Extended-spectrum cephalosporins 42 (62.7) 27 (40.3) 0.02 2.49 (1.24–5.00) 0.20 1.68 (0.76–3.75)
Flomoxef 17 (25.4) 11 (16.4) 0.28
Ureidopenicillins 29 (43.3) 31 (46.3) 0.86
Ureidopenicillins/β-lactamase inhibitors 30 (44.8) 34 (50.7) 0.60
Fluoroquinolones 27 (40.3) 17 (25.4) 0.10 1.98 (0.95–4.15) 0.13 1.90 (0.82–4.39)
Antifungal agents 8 (11.9) 8 (11.9) >0.99
Deﬁnitive therapy for ESBL-producing bacteraemia
Imipenem 10 (14.9) 19 (28.4) 0.09 0.44 (0.18–1.04) 0.46 0.68 (0.25–1.88)
Meropenem 6 (8.9) 9 (13.4) 0.59
Ertapenem 20 (29.9) 28 (41.8) 0.21
Flomoxef 24 (35.8) 8 (11.9) <0.01 4.12 (1.69–10.00) 0.03 2.99 (1.10–8.15)
Fluoroquinolones 7 (10.4) 3 (4.5) 0.33
Duration of therapy (days) 13 ± 8 14 ± 8 0.43
Data are presented as n (%) or mean ± SD. There was adequate goodness of ﬁt (Hosmer and Lemeshow test, χ2 = 9.02, p 0.34). Receiver operating characteristic analysis indicated
that predictive performance of logistic regression model was adequate (area under the curve = 0.92).
CI, conﬁdence interval; ESBL, extended-spectrum β-lactamase; ICU, intensive care unit; OR, odds ratio.
aPatients may have more than one underlying source of infection.
1105.e4 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIfrom different patients. Recurrent infections caused by iden-
tical isolates were found in 38 patients (67.8%), and the
remaining 18 patients (32.2%) with recurrent bacteraemia
were caused by different strains. Demographic and clinical
features of these patients are shown in Table 2. The in vitro
susceptibility and ESBL genotypes of the clinical isolates from
the ﬁrst episode of bacteraemia were similar between the
patients infected by identical strains and those by different
strains. The intervals (days) between the ﬁrst and the subse-
quent bacteraemia episodes or percentage of breakthrough
bacteraemia were also similar between the two groups. In the
multiple logistic regression analysis, deﬁnitive therapy with
ﬂomoxef (OR, 5.13; 95% CI, 1.22–21.63; p 0.03) was identiﬁed
as the independent factor associated with recurrent bacter-
aemia caused by identical strains. In addition, deﬁnitive therapy
with ﬂomoxef (OR, 7.10; 95% CI, 1.27–39.69; p 0.03)Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectremained an independent risk factor for recurrent ESBL-EC or
ESBL-KP bacteraemia caused by identical strains when the
analysis was only limited to the 41 patients without break-
through bacteraemia.
Microbiologic proﬁles of isolates from ESBL-EC or
ESBL-KP recurrent bacteraemia caused by identical
strains
Microbiologic proﬁles of the isolates (EC, 50 isolates from 23
patients; KP, 30 isolates from 15 patients) identiﬁed from the 38
patients with recurrent bacteraemia caused by identical strains
are provided in Supplementary Tables S1 and S2.
Comparison of the MICs between initial and subsequent
isolates from 38 patients with recurrent infections caused by
identical strains revealed that in 3 patients (7.9%) with ESBL-KP
bacteraemia, isolates from the second episodes demonstrated aious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1105.e1–1105.e8
TABLE 2. Demographic, clinical and epidemiologic features of adults bacteraemia due to ESBL-producing Escherichia coli or
Klebsiella pneumoniae: identical strains vs. different strains
Characteristic
Identical strains
(n [ 38)
Different strains
(n [ 18)
Univariate analysis Multivariate analysis
p OR (95% CI) p OR (95% CI)
Age (years) 63.2 ± 20.8 65.2 ± 15.4 0.93
Male 22 (57.9) 9 (50.0) 0.77
Hospital-acquired infection 31 (81.6) 16 (88.9) 0.70
E. coli infection 23 (60.5) 12 (66.7) 0.77
Antimicrobial resistance of initial isolates
Flomoxef 10 (26.3) 6 (33.3) 0.75
Ciproﬂoxacin 31 (81.6) 13 (72.2) 0.49
Piperacillin-tazobactam 7 (18.4) 1 (5.6) 0.41
Ertapenem 3 (7.9) 1 (5.6) >0.99
ESBL genotype of initial isolates
SHV-12 12 (31.6) 8 (44.4) 0.38
CTX-M-14 16 (42.1) 9 (50.0) 0.77
CTX-M-15 22 (57.9) 12 (66.7) 0.57
Polymicrobial bloodstream infection 7 (18.4) 4 (22.2) 0.73
Bacteraemic onset in ICU 27 (71.1) 16 (88.9) 0.19
Pittsburgh bacteraemic score 4 points 29 (76.3) 13 (72.2) 0.75
Comorbidity
Diabetes mellitus 14 (36.8) 8 (44.4) 0.77
Malignancy 16 (42.1) 6 (33.3) 0.57
Liver cirrhosis 5 (13.2) 3 (16.7) 0.70
Renal failure 16 (42.1) 8 (44.4) >0.99
Hemodialysis dependence 7 (18.4) 2 (11.1) 0.70
Source of infectiona
Urinary tract infection 16 (42.1) 4 (22.2) 0.23
Catheter-related urinary tract infection 9 (23.7) 2 (11.1) 0.47
No identiﬁed focus 8 (21.1) 7 (38.9) 0.20
Pneumonia 5 (13.2) 6 (33.3) 0.15
Vascular catheter–related infection 14 (36.8) 8 (44.4) 0.77
Removal of catheter within 72 hours after bacteraemia for
vascular catheter infection
8 (57.1) 6 (75.0) 0.65
Intra-abdominal infection 4 (10.5) 2 (11.1) >0.99
Skin and soft tissue infection 4 (10.5) 1 (5.6) >0.99
Time between episodes (days) 26 ± 21 27 ± 23 0.13
Breakthrough bacteraemia 12 (31.6) 3 (16.7) 0.34
Antimicrobial therapy within 4 weeks before bacteraemia
Glycopeptides 12 (31.6) 6 (33.3) >0.99
Carbapenems 10 (26.3) 2 (11.1) 0.30
Extended-spectrum cephalosporins 22 (57.9) 9 (50.0) 0.77
Flomoxef 8 (21.1) 4 (22.2) >0.99
Ureidopenicillins 22 (57.9) 7 (38.9) 0.25
Ureidopenicillins/β-lactamase inhibitor 18 (47.4) 7 (38.9) 0.58
Fluoroquinolones 18 (47.4) 7 (38.9) 0.58
Antifungal agents 4 (10.5) 1 (5.6) >0.99
Deﬁnitive therapy for ESBL-producing bacteraemia
Imipenem 5 (13.2) 2 (11.1) >0.99
Meropenem 2 (5.3) 3 (16.7) 0.31
Ertapenem 8 (21.1) 6 (33.3) 0.34
Flomoxef 21 (55.3) 3 (16.7) <0.01 6.18 (1.53–24.92) 0.03 5.13 (1.22–21.63)
Fluoroquinolones 2 (5.3) 4 (22.2) 0.08 0.19 (0.03–1.18) 0.29 0.37 (0.06–2.37)
Duration of therapy (days) 14 ± 6 13 ± 8 0.82
Data are presented as n (%) or mean ± SD. There was adequate goodness of ﬁt (Hosmer and Lemeshow test, χ2 = 3.55, p 0.89). Receiver operating characteristic analysis indicated
that predictive performance of logistic regression model was adequate (area under the curve = 0.91).
CI, conﬁdence interval; ESBL, extended-spectrum β-lactamase; ICU, intensive care unit; OR, odds ratio.
aPatients may have more than one underlying source of infection.
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(Supplementary Table S2). One patient (KP8) had a recurrent
bacteraemia at 21 days after ﬂomoxef therapy. In addition to
the prior existed blaSHV-12, the mutational changes in ompK35
and ompK36 and the acquisition of blaDHA-1 in the identical
isolate from the second episode may well explain its diminished
susceptibility to imipenem and meropenem. Another two pa-
tients (KP7 and KP14) developed breakthrough bacteraemia.
The initial isolate KP7-1 already had a blaSHV-12 and an IS10
insertion in the ompK35. After receiving ﬂomoxef therapy for 5
days, patient KP7 developed a recurrent episode of bacteraemia
caused by KP7-2 (identical strain) that had developed an extraClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfeOmpK36 deﬁciency, resulting in ertapenem resistance and
diminished susceptibility to imipenem and meropenem. The
remaining patient, patient KP14, received imipenem therapy for
4 days before the development of a recurrent episode of ESBL-
KP bacteraemia caused by an identical strain. From the initial
isolate that had blaSHV-12 and blaCMY-2 and OmpK35 deﬁciency
by IS10 insertion, an extra OmpK36 deﬁciency was also found in
the identical isolate by IS10 insertion, leading to imipenem and
meropenem resistance. Such signiﬁcant changes in the carba-
penem MICs were not found in the ESBL-EC isolates causing
recurrent bacteraemia caused by identical strains
(Supplementary Table S1).ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1105.e1–1105.e8
1105.e6 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIDiscussionPatients with bloodstream infections may experience recurrent
bacteraemia after an apparent recovery from the initial episode.
To our knowledge, this is the ﬁrst study to investigate the
incidence and clinical and microbiologic features of recurrent
bacteraemia caused by ESBL-EC and ESBL-KP. In this study, we
observed a substantial rate (16.7%) of recurrent bacteraemia
due to ESBL-producing bacteria. This ﬁnding is similar to that
reported for non-typhoid Salmonella bacteraemia (15.7%) [8]
but differs from those observed in bacteraemia due to Staphy-
lococcus aureus (20.3%) [9], E. coli (6.3%) [10], Acinetobacter
baumannii (5.6%) [11] and Streptococcus pneumoniae (2.3%) [12].
Through PFGE analysis, we further found that 67.8% of the
cases were caused by identical strains. The rate was higher than
that reported for other Gram-negative bacteria (48%) [10,11]
but was slightly lower than that reported for S. aureus
(90.6%) [9]. Similar to the role of S. aureus as a skin commensal,
E. coli and K. pneumoniae are normal inhabitants of the human
gastrointestinal tract. Many reports have indicated that previous
gastrointestinal carriage is closely associated with the devel-
opment or recurrence of any type of infection, including bac-
teraemia, by ESBL-producing organisms [28]. Patients with
recurrent bacteraemia caused by identical strains might have
residual foci of infection or persistent reservoirs that were not
eliminated during the treatment of the prior episodes. It has
been indicated that even with effective treatment, the intestinal
tract can still be colonized with Enterobacteriaceae strains of the
same sequence types and resistance genotypes, leading to the
subsequent recurrent infection [29].
Analysis of the clinical features of patients in the present
study revealed that recurrent ESBL-EC or ESBL-KP bacteraemia
was independently associated with bacteraemia resulting from
vascular catheter–related infection. It is also not surprising to
ﬁnd recurrent bacteraemia in patients who used vascular
catheters. A study that assessed the relapse in patients with
catheter-related bacteraemia due to Gram-negative bacilli also
demonstrated similar ﬁndings. Although catheter removal
within 72 hours of the onset of the bacteraemia was found to
be the only independent protective factor against relapse [30],
our study failed to identify the strategy of catheter removal
shortly after onset of bacteraemia as a protective factor asso-
ciated with recurrent bacteraemia caused by ESBL-EC and
ESBL-KP in our patients. The sample size of vascular cath-
eter–related infection in our study might be too small to draw
the same conclusion.
Patients with bacteraemia due to antimicrobial-resistant or-
ganisms usually have been exposed to certain classes of anti-
biotics before disease onset. However, in the present study,Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectonly the use of ﬂomoxef as deﬁnitive therapy for the initial
bacteraemia was independently associated with recurrent bac-
teraemia by ESBL-EC or ESBL-KP. Cephamycins have good
in vitro activity and stability in resisting hydrolysis by ESBLs
produced by microorganisms and have been shown to be as
effective as carbapenems in the treatment of bacteraemia
caused by cephamycin-susceptible ESBL-KP [3]. Nevertheless,
bacteraemic relapses by ESBL-KP organisms that acquired
foreign resistance genes and/or other resistance mechanisms
during ﬂomoxef therapy have been reported [6]. Several studies
also indicated that compared to noncarbapenem agents, car-
bapenem treatment for infections due to ESBL-producing or-
ganisms may be associated with better outcomes and with
lower sepsis-related mortality [1,31]. Another study reported
that breakthrough bacteraemia developed in eight of 16 patients
with ertapenem-susceptible KP bacteraemia, but only one of
the breakthrough bacteraemia cases occurred during carbape-
nem therapy [32]. Consequently, the bactericidal activity and
the occurrence of resistant mutants may vary during or after
carbapenem and cephamycin therapy.
The ﬁndings of our study suggest that ﬂomoxef treatment in
ESBL-producing bacteraemia might not effectively eliminate the
infected reservoir during the ﬁrst episode, thereby increasing
the risk of recurrent bacteraemia caused by identical strains.
Indeed, several strains of ESBL-EC and ESBL-KP resistant to
cephamycins via impermeability have been reported. This
phenomenon has been more frequently described in KP than in
EC [6,33,34]. Similarly in the present study, two of the nine
patients presented with recurrent ESBL-KP infection caused by
identical strains that demonstrated decreased expression of the
outer membrane proteins during or after ﬂomoxef therapy, but
the phenomenon was not found in any of the 12 patients with
recurrent ESBL-EC infection caused by identical strains.
Impermeability plays an important role in the carbapenem
resistance of ESBL-KP isolates [35]. The contribution of
ompK36 to carbapenem resistance in KP has been reported
[36]. However, in three carbapenem-nonsusceptible ESBL-KP
isolates, KP9-1, KP9-2 and KP14-1, we could not ﬁnd any ge-
netic change in the ompK36 gene. Whether or not other
mechanisms existed and affected the expression of ompK36
remains to be explored.
This study has certain limitations. First, because this was a
hospital-based retrospective study, we could only analyse in-
hospital data and perform microbiologic investigations on a
fraction of the ESBL-EC and ESBL-KP isolates. Second, the
case–control analysis provides data only among the patients
who had an initial episode of bacteraemia followed by a second
episode of bacteraemia. The ﬁndings are therefore relevant to
only a small proportion of the population. The rates presented
should therefore be viewed as conservative estimates of all trueious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1105.e1–1105.e8
CMI Lee et al. Recurrent bacteraemia and ESBL-producing bacteria 1105.e7recurrent bacteraemia in the population studies. Third, in-
dividuals with ESBL-EC or ESBL-KP bacteraemia were com-
bined for analysis, though E. coli and K. pneumoniae are generally
assumed to behave similarly, and combining such patients in the
same analysis is common in the literature [27]. Fourth, the
results obtained in the present study may not be generalized to
other settings as a result of differences in antibiotic prescription
practices and geographic differences in patient characteristics
and antimicrobial susceptibility. Lastly, we did not perform
environmental cultures, and we therefore could not assess the
contribution of patients’ immediate surroundings to the
recurrent infection episodes.
We conclude that recurrent ESBL-EC or ESBL-KP bacter-
aemia is not uncommon among our patients, particularly in
patients having vascular catheters and receiving ﬂomoxef
therapy. In most of the cases of recurrent bacteraemia, the
genetic backgrounds of the aetiologic agents of the primary and
recurrent infections are similar, and increased resistance to
carbapenems may occur in ESBL-KP isolates that cause recur-
rent episodes of bacteraemia.Transparency DeclarationThis study was sponsored by Merck & Co. Ltd. and was sup-
ported by the Chang Gung Memorial Hospital, Taiwan (CMRPG
8C1031). C.-H. Lee has received research support from Merck.
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